Literature DB >> 17955779

Hepatitis B surface antigen, hepatitis C and HIV antibodies in a low-risk blood donor group, Nigeria.

D Z Egah1, E B Banwat, E S Audu, D Iya, B M Mandong, A A Anele, N E Gomwalk.   

Abstract

We investigated the seroprevalence of human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) infection among 258 clergymen-in-training (age range 18-39 years) who represented a donor population that fulfilled the criteria for safe blood transfusion. In all, 15.1% of the men were positive for HBsAg, 4.3% were positive for anti-HCV and 2.7% were HIV-positive; 22.1% were infected with at least one of these viruses. Co-infection with HIV and HBV was found in 0.4% of the subjects, HBV and HCV in 0.4%, and HIV and HCV in 0%. This underscores the importance of routine screening of blood before transfusion, regardless of the donor background.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17955779

Source DB:  PubMed          Journal:  East Mediterr Health J        ISSN: 1020-3397            Impact factor:   1.628


  11 in total

Review 1.  Blood transfusion safety in Africa: a literature review of infectious disease and organizational challenges.

Authors:  Evan M Bloch; Marion Vermeulen; Edward Murphy
Journal:  Transfus Med Rev       Date:  2011-08-26

2.  Rates and impact of hepatitis on human immunodeficiency virus infection in a large African cohort.

Authors:  Nimzing Gwamzhi Ladep; Patricia Aladi Agaba; Oche Agbaji; Auwal Muazu; Placid Ugoagwu; Godwin Imade; Graham Cooke; Sheena McCormack; Simon David Taylor-Robinson; John Idoko; Phyllis Kanki
Journal:  World J Gastroenterol       Date:  2013-03-14       Impact factor: 5.742

3.  HIV and HBsAg Seropositivity Amongst Patients Presenting for Ocular Surgery at a Tertiary Eye Care Hospital in Nigeria.

Authors:  M B Alhassan; P Unung; Go Adejor
Journal:  Open Ophthalmol J       Date:  2013-03-22

4.  The challenges of meeting the blood transfusion requirements in Sub-Saharan Africa: the need for the development of alternatives to allogenic blood.

Authors:  Erhabor Osaro; Adias Teddy Charles
Journal:  J Blood Med       Date:  2011-02-06

5.  The prevalence of hepatitis B and C viral infections among pregnant women.

Authors:  Ose Ugbebor; Moses Aigbirior; Favour Osazuwa; Ehigha Enabudoso; Omorogbe Zabayo
Journal:  N Am J Med Sci       Date:  2011-05

6.  New strains of hepatitis B virus genotype E circulating in Nigeria.

Authors:  Bankole H Oladeinde; Ifeoma M Ekejindu; Richard Omoregie; Ikpomwonosa Odia; Obiora D Aguh; Uchechukwu M Okwu
Journal:  Int J Health Sci (Qassim)       Date:  2018 Nov-Dec

7.  Prevalence and Risk Factors of Human Immunodeficiency Virus and Hepatitis C Virus Infection among Pregnant Women Attending Antenatal Care at a Tertiary Hospital in Abuja, Nigeria.

Authors:  Chris Ovoroyeguono Agboghoroma; Binyerem Chigbonwu Ukaire
Journal:  Niger Med J       Date:  2020-10-13

8.  Sero-prevalence of hepatitis B virus and hepatitis C virus among HIV patients in a suburban University Teaching Hospital in South-East Nigeria.

Authors:  Chiekulie Kevin Diwe; Emmanuel Chidiebere Okwara; Oguamanam Okezie Enwere; Jerome Emeka Azike; Nathan Chibuzo Nwaimo
Journal:  Pan Afr Med J       Date:  2013-09-10

9.  Time trends of seroepidemiology of hepatitis C virus and hepatitis B virus coinfection in human immunodeficiency virus-infected patients in a Super Specialty Hospital in New Delhi, India: 2012-2014.

Authors:  Abha Sharma; Jasmin Halim; Tavleen Jaggi; Bibhabati Mishra; Archana Thakur; Vinita Dogra; Poonam Sood Loomba
Journal:  Indian J Sex Transm Dis AIDS       Date:  2016 Jan-Jun

10.  Twenty-Year Evolution of Hepatitis B Virus and Human Immunodeficiency Virus Prevalence and Incidence in Voluntary Blood Donors in Côte d'Ivoire.

Authors:  Benjamin Seri; Albert Minga; Delphine Gabillard; Bamori Dembele; Seidou Konate; Jérôme Le Carrou; Lambert Dohoun; Yao Abo; Sophie Karcher; Patrick Coffie; Thérèse N'Dri-Yoman; Alain Attia; Serge P Eholié; Christine Danel; Karine Lacombe; Xavier Anglaret; Anders Boyd
Journal:  Open Forum Infect Dis       Date:  2018-03-16       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.